Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CureVac COVID vaccine let-down spotlights mRNA design challenges.

× No keyword cloud information.

3 in total

1. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors: Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal: Immunity Date: 2005-08 Impact factor: 31.745

2. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.

Authors: Laith J Abu-Raddad; Hiam Chemaitelly; Adeel A Butt
Journal: N Engl J Med Date: 2021-05-05 Impact factor: 91.245

3. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Authors: Aziz Sheikh; Jim McMenamin; Bob Taylor; Chris Robertson
Journal: Lancet Date: 2021-06-14 Impact factor: 79.321

3 in total

19 in total

1. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery.

Authors: Jilian R Melamed; Khalid A Hajj; Namit Chaudhary; Daria Strelkova; Mariah L Arral; Norbert Pardi; Mohamad-Gabriel Alameh; Jason B Miller; Lukas Farbiak; Daniel J Siegwart; Drew Weissman; Kathryn A Whitehead
Journal: J Control Release Date: 2021-11-18 Impact factor: 9.776

Review 10. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.

Authors: John S Tregoning; Katie E Flight; Sophie L Higham; Ziyin Wang; Benjamin F Pierce
Journal: Nat Rev Immunol Date: 2021-08-09 Impact factor: 53.106

CureVac COVID vaccine let-down spotlights mRNA design challenges.

1. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

2. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.

3. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

1. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery.

Review 2. mRNA-based modalities for infectious disease management.

Review 3. Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges.

Review 4. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities.

5. mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnology.

Review 6. Principles for designing an optimal mRNA lipid nanoparticle vaccine.

Review 7. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects.

Review 8. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies.

Review 9. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.

Review 10. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.